El estudio del sedimento urinario es una fuente de información muy importante en la valoración de la lesión renal y más cuando alrededor del 20% de la población general sufre afecciones en el aparato urinario. "Desde mi experiencia, en un sólo Instituto de Urología, Nefrología y Andrología, que se dedica a tratar este tipo de problemas, se efectúan más de 60.000 visitas ambulatorias anuales y casi 4.000 intervenciones quirúrgicas", afirma el Dr. Fernando Dalet, miembro de la Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC).
Al igual que en otras patologías, el diagnóstico precoz de las lesiones renales es fundamental y, para ello, son de vital importancia las pruebas para conseguirlo. En este sentido, la Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC) pretende poner sobre la mesa el importante papel de las pruebas de laboratorio para determinar la mayoría de las afecciones asociadas al aparato urinario. Para ello, ha organizado el seminario Distinción de los hematíes de origen glomerular: ¿una quimera o una herramienta útil de diagnóstico clínico?, patrocinado por la Fundación José Luis Castaño para el desarrollo de la Bioquímica Clínica.
"El sedimento urinario es, en la práctica, el último de los análisis manuales con valoración final subjetiva, lo que significa, en pocas palabras, que cuanto más sabe y mayor experiencia tiene el investigador mejores y más especializados resultados se obtienen", explica el Dr. Dalet. "De ahí, la importancia de generar conocimiento e informar sobre las novedades en este campo ya que, como en todo, existen casos fáciles de rápido diagnóstico y otros de gran complejidad", añade el experto.
Hoy en día, se disponen de diferentes pruebas para determinar si una persona sufre o no enfermedad renal. "Existen las pruebas diagnósticas por la imagen (radiografías, ecografías y TAC), las de visualización directa (endoscopia) y las analíticas. "Casi todas, excepto la ecografía y la orina son pruebas invasivas, es decir, se atenta contra la integridad del paciente y siempre existe un cierto riesgo", pone de manifiesto el Dr. Dalet. Este motivo y otros como la seguridad, su fácil obtención y su bajísimo coste llevan a los expertos a recomendar esta prueba diagnóstica.
-Los hematíes como herramienta de diagnóstico clínico
La hematuria (pérdida de sangre por la orina) es un signo (no un síntoma) que alerta inmediatamente no sólo al clínico sino también al enfermo, el cual acude presuroso a la consulta del médico. "La razón fundamental de este hecho es que todas las patologías urológicas y casi todas las nefrológicas presentan este signo", explica el Dr. Dalet.
Actualmente, el laboratorio clínico dispone de un método que investiga las anomalías morfológicas de los hematíes y según el resultado se clasifica la hematuria en isomórfica o dismórfica. "La hematuria isomórfica procede del vertido directo de los capilares sanguíneos al torrente urinario, tal y como se produce en las enfermedades urológicas, así que puede derivarse el enfermo al urólogo", afirma el Dr. Dalet. "Por el contrario, añade el experto, la hematuria dismórfica proviene de la filtración a través de la unidad nefrónica e indica una lesión del glomérulo. Esto significa que este tipo de hematurias estarán presentes, exclusivamente, en las enfermedades de origen nefrológico propias del riñón, o bien, en aquellas de carácter sistémico con repercusión en el riñón como la hipertensión, la diabetes, gota o dislipemias, entre otras".
En este sentido y como conclusión, el Dr. Dalet comenta que "gracias a una simple prueba de orina, que tiene un coste muy bajo para el Sistema Nacional de Salud, podemos controlar y hacer el seguimiento del elevado número de personas que por encima de los 50 años tiene una o varias de las patologías anteriormente descritas. Esto supone un reto y un cambio de actitud ya que, todavía, se siguen realizando costosos análisis de sangre como seguimiento de estos pacientes".
Diario digital con noticias de actualidad relacionadas con el mundo de la salud. Novedades, encuestas, estudios, informes, entrevistas. Con un sencillo lenguaje dirigido a todo el mundo. Y algunos consejos turísticos para pasarlo bien
Traductor
05 October 2011
A shot of cortisone stops traumatic stress
As soldiers return home from tours in Afghanistan and Iraq, America must cope with the toll that war takes on mental health. But the treatment of Post Traumatic Stress Disorder (PTSD) is becoming increasingly expensive, and promises to escalate as yet another generation of veterans tries to heal its psychological wounds. New hope for preventing the development of PTSD has been uncovered by Prof. Joseph Zohar of Tel Aviv University's Sackler Faculty of Medicine and the Sheba Medical Center, in collaboration with Prof. Hagit Cohen from Ben-Gurion University -- and the key is a single dose of a common medication.
When a person suffers trauma, the body naturally increases its secretion of cortisone. Taking this natural phenomenon into account, Prof. Zohar set out to discover what a single extra dose of cortisone could do, when administered up to six hours after test subjects experienced a traumatizing event. The results, which will be published in the journal European Neuropsychopharmacology in October 2011, indicate that the likelihood that the patient will later develop PTSD is reduced by 60 percent.
-Opening the window of opportunity
In most psychiatric conditions, it is impossible to establish a precise point of time at which the disorder manifested, Prof. Zohar says. But PTSD is unique in that is has an easily established timeline, beginning from the moment a patient experiences trauma. This makes PTSD eligible for treatment in the "golden hours" -- a medical term that defines the precious few hours in which treatment can be most beneficial following a trauma, heart attack, stroke, or medical event. Receiving treatment in this window of opportunity can be critical.
In their animal models, Prof. Zohar and his fellow researchers first began treating PTSD in the window of opportunity up to six hours after a traumatic event. Two groups of rats were exposed to the smell of a cat, and one group was treated with cortisone after the event.
Following promising results with the rats, the researchers initiated a double-blind study in an emergency room, in which trauma victims entering the hospital were randomly assigned to receive a placebo or the cortisone treatment. Follow-up exams took place two weeks, one month, and three months after the event. Those patients who had received a shot of cortisone were more than sixty percent less likely to develop PTSD, they discovered.
**Source: American Friends of Tel Aviv University
When a person suffers trauma, the body naturally increases its secretion of cortisone. Taking this natural phenomenon into account, Prof. Zohar set out to discover what a single extra dose of cortisone could do, when administered up to six hours after test subjects experienced a traumatizing event. The results, which will be published in the journal European Neuropsychopharmacology in October 2011, indicate that the likelihood that the patient will later develop PTSD is reduced by 60 percent.
-Opening the window of opportunity
In most psychiatric conditions, it is impossible to establish a precise point of time at which the disorder manifested, Prof. Zohar says. But PTSD is unique in that is has an easily established timeline, beginning from the moment a patient experiences trauma. This makes PTSD eligible for treatment in the "golden hours" -- a medical term that defines the precious few hours in which treatment can be most beneficial following a trauma, heart attack, stroke, or medical event. Receiving treatment in this window of opportunity can be critical.
In their animal models, Prof. Zohar and his fellow researchers first began treating PTSD in the window of opportunity up to six hours after a traumatic event. Two groups of rats were exposed to the smell of a cat, and one group was treated with cortisone after the event.
Following promising results with the rats, the researchers initiated a double-blind study in an emergency room, in which trauma victims entering the hospital were randomly assigned to receive a placebo or the cortisone treatment. Follow-up exams took place two weeks, one month, and three months after the event. Those patients who had received a shot of cortisone were more than sixty percent less likely to develop PTSD, they discovered.
**Source: American Friends of Tel Aviv University
Los especialistas se reúnen en el International EuroSpine 2011 Congress en Milán
El congreso europeo para terapia, cirugía y ortopedia espinal tendrá lugar en Milán (Italia) del 19 al 21 de octubre y atraerá a numerosos expertos médicos y especialistas industriales de todo el mundo. Miles de participantes intercambiarán su conocimiento profundo sobre los últimos resultados de búsqueda, tecnologías y métodos de tratamiento.
EuroSpine - The Spine Society of Europe, respalda la campaña DECADE OF ACTION FOR ROAD SAFETY (http://www.decadeofaction.org) iniciada por Naciones Unidas y coordinada por la Organización Mundial de la Salud (OMS) lanzada en todo el mundo en 2011.
Las lesiones producidas por accidentes de tráfico se convertirán en la quinta mayor causa de muerte para 2030, resultando en 2,4 millones de fallecimiento al año. Los miembros de la EuroSpine Society por virtud, afrontan las consecuencias de accidentes de tráfico. Los traumas espinales provocados por las colisiones de tráfico son una de las principales razones para las lesiones de la médula espinal y problemas relacionados. Las sociedades académicas como EuroSpine se dedican principalmente a enseñar y promocionar los mejores estándares de práctica para tratar a los pacientes de sufren lesiones de la médula espinal debido a accidentes de tráfico.
Durante el congreso de este año tendrá lugar una rueda de prensa internacional el 19 de octubre de 2011 en el Milan Congress Center (MiCo), donde expertos espinales reconocidos responderán a las preguntas de los representantes de medios interesados.
Participantes de la rueda de prensa:
- Prof. Dr. Ciaran Bolger (presidente de la EuroSpine Society) , Prof. Dr. Jean-Charles Le Huec (vicepresidente de la EuroSpine Society), Prof. Dr. Haluk Berk (secretario de la EuroSpine Society), Prof. Dr. Ahmet Alanay (presidente de EuroSpine 2011 Program Committee), Prof. Dr. Claudio Lamartina (anfitrión local de EuroSpine 2011) y el Prof. Dr. Marco Brayda-Bruno (anfitrión local de EuroSpine 2011)
EuroSpine - The Spine Society of Europe, respalda la campaña DECADE OF ACTION FOR ROAD SAFETY (http://www.decadeofaction.org) iniciada por Naciones Unidas y coordinada por la Organización Mundial de la Salud (OMS) lanzada en todo el mundo en 2011.
Las lesiones producidas por accidentes de tráfico se convertirán en la quinta mayor causa de muerte para 2030, resultando en 2,4 millones de fallecimiento al año. Los miembros de la EuroSpine Society por virtud, afrontan las consecuencias de accidentes de tráfico. Los traumas espinales provocados por las colisiones de tráfico son una de las principales razones para las lesiones de la médula espinal y problemas relacionados. Las sociedades académicas como EuroSpine se dedican principalmente a enseñar y promocionar los mejores estándares de práctica para tratar a los pacientes de sufren lesiones de la médula espinal debido a accidentes de tráfico.
Durante el congreso de este año tendrá lugar una rueda de prensa internacional el 19 de octubre de 2011 en el Milan Congress Center (MiCo), donde expertos espinales reconocidos responderán a las preguntas de los representantes de medios interesados.
Participantes de la rueda de prensa:
- Prof. Dr. Ciaran Bolger (presidente de la EuroSpine Society) , Prof. Dr. Jean-Charles Le Huec (vicepresidente de la EuroSpine Society), Prof. Dr. Haluk Berk (secretario de la EuroSpine Society), Prof. Dr. Ahmet Alanay (presidente de EuroSpine 2011 Program Committee), Prof. Dr. Claudio Lamartina (anfitrión local de EuroSpine 2011) y el Prof. Dr. Marco Brayda-Bruno (anfitrión local de EuroSpine 2011)
Roche and Diagnostica Stago Terminate Partnership
Roche Professional Diagnostics and Diagnostica Stago announced today that the companies have decided to pursue separate paths in the business of Laboratory Coagulation in the territories where Roche distributed the Stago product range. The exclusive sales of Stago products by Roche will continue throughout the entire year of 2011. With the exception of Japan, where Roche Diagnostics Japan will continue to distribute the Stago portfolio within the Japanese market under a separate agreement, Stago will sell its products directly or through other distribution channels.
Stago and Roche have an agreement to ensure that all contractual obligations regarding Stago products that Roche has or will enter into can be fulfilled by Roche during the agreed upon three year transition period.
"The arrangements between Stago and Roche provide our customers with a secure way forward. We have made sure that product supply continues without interruption, and customers can rely on both Roche and Stago to continue to fulfill their needs in laboratory coagulation," said Colin Brown, Head of Roche Professional Diagnostics.
Bertrand Bonnot, COO of Stago, said, "We are convinced that, after almost 40 years of successful partnership, it is the right timing for both companies to follow independent paths. Nevertheless, both Stago and Roche are committed to work together to ensure a seamless transition in the coming years."
Both Roche and Stago remain committed to respond to current and future needs of hemostasis customers.
Stago and Roche have an agreement to ensure that all contractual obligations regarding Stago products that Roche has or will enter into can be fulfilled by Roche during the agreed upon three year transition period.
"The arrangements between Stago and Roche provide our customers with a secure way forward. We have made sure that product supply continues without interruption, and customers can rely on both Roche and Stago to continue to fulfill their needs in laboratory coagulation," said Colin Brown, Head of Roche Professional Diagnostics.
Bertrand Bonnot, COO of Stago, said, "We are convinced that, after almost 40 years of successful partnership, it is the right timing for both companies to follow independent paths. Nevertheless, both Stago and Roche are committed to work together to ensure a seamless transition in the coming years."
Both Roche and Stago remain committed to respond to current and future needs of hemostasis customers.
Hysterectomy is associated with increased levels of iron in the brain
The human body has a love-hate relationship with iron. Just the right amount is needed for proper cell function, yet too much is associated with brain diseases like Alzheimer's and Parkinson's. Men have more iron in their bodies and brains than women. These higher levels may be part of the explanation for why men develop these age-related neurodegenerative diseases at a younger age.
But why do women have less iron in their systems than men? One possible explanation for the gender difference is that during menstruation, iron is eliminated through the loss of blood.
Now, a new study by UCLA researchers confirms this suspicion and suggests strategies to reduce excess iron levels in both men and women. Dr. George Bartzokis, a professor of psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA, and colleagues compared iron levels in women who had undergone a hysterectomy before menopause -- and thus, did not menstruate and lose iron -- with levels in postmenopausal women who had not had a premenopausal hysterectomy. They found the women who had undergone a hysterectomy had higher levels of iron in their brains than the women who hadn't, and further, they had levels that were comparable to men.
The research is reported in the current online edition of the journal Neurobiology of Aging.
The researchers used an MRI technique that can measure the amount of ferritin iron in the brain (ferritin is a protein that stores iron). They examined 39 postmenopausal women, 15 of whom had undergone a premenopausal hysterectomy. They looked at several areas in the brain three white-matter regions and and five gray-matter regions. Fifty-four male subjects were also imaged for comparison.
The researchers found that among the women, the 15 who had undergone a hysterectomy had concentrations of iron in the white-matter regions of the brain's frontal lobe that did not differ from the men's levels. Further, both the women who had a hysterectomy and the men had significantly higher amounts of iron than the women who had not undergone a hysterectomy. (Gray matter areas showed slight increases that were not statistically significant.)
Hysterectomy is the most common non-obstetrical surgery among women in the United States, with one in three having had a hysterectomy by age 60, said Bartzokis, who is also a member of the UCLA Laboratory of Neuro Imaging and the UCLA Brain Research Institute.
The results of this study, he said, suggest that menstruation-associated blood loss may explain gender differences in brain iron. And of interest to both men and women, he said, is that it's possible that brain iron can be influenced by peripheral iron levels -- that is, iron levels throughout the body -- and may thus be a modifiable risk factor for age-related degenerative diseases.
"Iron accumulates in our bodies as we age," Bartzokis said, "and in the brain contributes to the development of abnormal deposits of proteins associated with several prevalent neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies. Higher brain iron levels in men may be part of the explanation for why men develop these age-related neurodegenerative diseases at a younger age, compared to women."
Bartzokis suggests it may be possible to reduce age-related brain iron accumulations by reducing the levels of iron throughout the body. This may have health benefits, especially in men, and may help counteract the negative effects of aging on the brain by reducing the iron available to catalyze, or speed up, damaging free-radical reactions.
There are a few ways body stores of iron can be reduced naturally, especially for premenopausal women. Menstruation leads to the elimination of iron through loss of blood. During pregnancy, iron is transferred from the woman to the fetus, and when women breast-feed, iron is transferred to the baby through the mother's milk.
"But there are things postmenopausal women and especially men can do to reduce their iron levels through relatively simple actions," Bartzokis said. "These include not overloading themselves with over-the-counter supplements that contain iron, unless recommended by their doctor; eating less red meat, which contains high levels of iron; donating blood; and possibly taking natural iron-chelating substances, molecules that bind to and remove iron, such as curcumin or green tea, that may have positive health consequences."
Other study authors were Todd A. Tishler, Erika P. Raven, Po H. Lu and Lori L. Altshuler, all of UCLA. Funding was provided by the National Institutes of Health, the U.S. Department of Veterans Affairs and the RCS Alzheimer's Foundation.
**Source: University of California - Los Angeles
But why do women have less iron in their systems than men? One possible explanation for the gender difference is that during menstruation, iron is eliminated through the loss of blood.
Now, a new study by UCLA researchers confirms this suspicion and suggests strategies to reduce excess iron levels in both men and women. Dr. George Bartzokis, a professor of psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA, and colleagues compared iron levels in women who had undergone a hysterectomy before menopause -- and thus, did not menstruate and lose iron -- with levels in postmenopausal women who had not had a premenopausal hysterectomy. They found the women who had undergone a hysterectomy had higher levels of iron in their brains than the women who hadn't, and further, they had levels that were comparable to men.
The research is reported in the current online edition of the journal Neurobiology of Aging.
The researchers used an MRI technique that can measure the amount of ferritin iron in the brain (ferritin is a protein that stores iron). They examined 39 postmenopausal women, 15 of whom had undergone a premenopausal hysterectomy. They looked at several areas in the brain three white-matter regions and and five gray-matter regions. Fifty-four male subjects were also imaged for comparison.
The researchers found that among the women, the 15 who had undergone a hysterectomy had concentrations of iron in the white-matter regions of the brain's frontal lobe that did not differ from the men's levels. Further, both the women who had a hysterectomy and the men had significantly higher amounts of iron than the women who had not undergone a hysterectomy. (Gray matter areas showed slight increases that were not statistically significant.)
Hysterectomy is the most common non-obstetrical surgery among women in the United States, with one in three having had a hysterectomy by age 60, said Bartzokis, who is also a member of the UCLA Laboratory of Neuro Imaging and the UCLA Brain Research Institute.
The results of this study, he said, suggest that menstruation-associated blood loss may explain gender differences in brain iron. And of interest to both men and women, he said, is that it's possible that brain iron can be influenced by peripheral iron levels -- that is, iron levels throughout the body -- and may thus be a modifiable risk factor for age-related degenerative diseases.
"Iron accumulates in our bodies as we age," Bartzokis said, "and in the brain contributes to the development of abnormal deposits of proteins associated with several prevalent neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies. Higher brain iron levels in men may be part of the explanation for why men develop these age-related neurodegenerative diseases at a younger age, compared to women."
Bartzokis suggests it may be possible to reduce age-related brain iron accumulations by reducing the levels of iron throughout the body. This may have health benefits, especially in men, and may help counteract the negative effects of aging on the brain by reducing the iron available to catalyze, or speed up, damaging free-radical reactions.
There are a few ways body stores of iron can be reduced naturally, especially for premenopausal women. Menstruation leads to the elimination of iron through loss of blood. During pregnancy, iron is transferred from the woman to the fetus, and when women breast-feed, iron is transferred to the baby through the mother's milk.
"But there are things postmenopausal women and especially men can do to reduce their iron levels through relatively simple actions," Bartzokis said. "These include not overloading themselves with over-the-counter supplements that contain iron, unless recommended by their doctor; eating less red meat, which contains high levels of iron; donating blood; and possibly taking natural iron-chelating substances, molecules that bind to and remove iron, such as curcumin or green tea, that may have positive health consequences."
Other study authors were Todd A. Tishler, Erika P. Raven, Po H. Lu and Lori L. Altshuler, all of UCLA. Funding was provided by the National Institutes of Health, the U.S. Department of Veterans Affairs and the RCS Alzheimer's Foundation.
**Source: University of California - Los Angeles
Stroke rate 25 percent higher for Metis
The stroke rate among Manitoba Metis is nearly 25 percent higher than for other Manitobans, according to a study by the University of Manitoba and the Manitoba Metis Federation (MMF) presented October 4 at the Canadian Stroke Congress. The higher stroke rate is driven by a 53 percent higher smoking rate, 34 percent higher rate of diabetes, and 13 percent higher rate of high blood pressure among Metis aged 40 years and older, compared to all other Manitobans. High blood pressure, smoking and diabetes are leading risk factors for stroke.
"Being historically of both First Nation and European ancestries, but not really identifying as either one, Metis are a very unique people, but little research has been done on this population," says Dr. Judith Bartlett of the University of Manitoba and the MMF. "It's really difficult for a health system to put in place Metis-specific programs if they don't understand what that means. Our job through this study is to link the health authorities with the Metis to bridge that knowledge gap."
The study linked the MMF membership list and several Canadian Community Health Survey cycles with Manitoba Health's hospital records throughout the province to create the Metis Population Data-Base, a one-of-a-kind registry of the 73,000 Metis in the province.
"Despite universal health care, it is clear that stroke and related conditions are even more significant issues for Manitoba Metis than for all other residents in the province," the study says.
What are called "knowledge networks" of Metis and provincial Regional Health Authority (RHA) staff have now been established in each of the Manitoba Metis Federation's seven regions to look at the information from the study and interpret it within a local context, says Julianne Sanguins, Ph.D, of the Faculty of Medicine at the University of Manitoba and the MMF.
During the first few meetings of these knowledge networks, Metis Regions learned about available resources and the health-care providers discovered the strength of the Metis presence in their community, Dr. Sanguins says.
The ultimate purpose of these networks is to raise awareness about existing health services and then to make any necessary changes to the programs in each of the MMF/RHA regions to better meet the cultural needs of the Metis citizens.
"It is important to learn more about the unique health challenges of Canada's Metis population in order to control risk factors and prevent stroke," says Dr. Antoine Hakim, CEO and Scientific Director of the Canadian Stroke Network. "This study provides valuable information to create targeted education and outreach initiatives.''
"Aboriginal people are twice as likely to die from stroke than the general Canadian population," says Heart and Stroke Foundation spokesperson Dr. Michael Hill. "They are more likely to have high blood pressure and type 2 diabetes, putting First Nations, Inuit and Metis people at an even greater risk of stroke than the general population."
He says that culturally appropriate prevention strategies and novel health-care solutions will improve outcomes. "Awareness of how to control risk factors such as high blood pressure, obesity, physical activity, diabetes, and smoking is essential."
**Source: Heart and Stroke Foundation of Canada
"Being historically of both First Nation and European ancestries, but not really identifying as either one, Metis are a very unique people, but little research has been done on this population," says Dr. Judith Bartlett of the University of Manitoba and the MMF. "It's really difficult for a health system to put in place Metis-specific programs if they don't understand what that means. Our job through this study is to link the health authorities with the Metis to bridge that knowledge gap."
The study linked the MMF membership list and several Canadian Community Health Survey cycles with Manitoba Health's hospital records throughout the province to create the Metis Population Data-Base, a one-of-a-kind registry of the 73,000 Metis in the province.
"Despite universal health care, it is clear that stroke and related conditions are even more significant issues for Manitoba Metis than for all other residents in the province," the study says.
What are called "knowledge networks" of Metis and provincial Regional Health Authority (RHA) staff have now been established in each of the Manitoba Metis Federation's seven regions to look at the information from the study and interpret it within a local context, says Julianne Sanguins, Ph.D, of the Faculty of Medicine at the University of Manitoba and the MMF.
During the first few meetings of these knowledge networks, Metis Regions learned about available resources and the health-care providers discovered the strength of the Metis presence in their community, Dr. Sanguins says.
The ultimate purpose of these networks is to raise awareness about existing health services and then to make any necessary changes to the programs in each of the MMF/RHA regions to better meet the cultural needs of the Metis citizens.
"It is important to learn more about the unique health challenges of Canada's Metis population in order to control risk factors and prevent stroke," says Dr. Antoine Hakim, CEO and Scientific Director of the Canadian Stroke Network. "This study provides valuable information to create targeted education and outreach initiatives.''
"Aboriginal people are twice as likely to die from stroke than the general Canadian population," says Heart and Stroke Foundation spokesperson Dr. Michael Hill. "They are more likely to have high blood pressure and type 2 diabetes, putting First Nations, Inuit and Metis people at an even greater risk of stroke than the general population."
He says that culturally appropriate prevention strategies and novel health-care solutions will improve outcomes. "Awareness of how to control risk factors such as high blood pressure, obesity, physical activity, diabetes, and smoking is essential."
**Source: Heart and Stroke Foundation of Canada
El sindicato médico alerta: los recortes hacen la sanidad pública "insostenible
Los recortes de la Generalitat han empujado la sanidad pública catalana al borde de cruzar la línea roja: la que marca la incapacidad de mantener la calidad asistencial de los usuarios del servicio. Así lo han denunciado hoy representantes del sindicato médico de los ocho grandes hospitales de Cataluña. Estos mantienen cerca del 30% de camas cerradas y cuatro de cada diez quirófanos clausurados, lo que unido al recorte de personal, horas extra y turnos de guardia ha dejado a los hospitales bajo mínimos. "Pedimos al presidente de la Generalitat, Artur Mas, que de forma urgente dote a la sanidad pública de los 77 millones de euros que necesita desesperadamente para poder trabajar a pleno rendimiento y con la calidad asistencial que se merecen los usuarios", ha resumido la representante del Sindicato de Médicos en el hospital barcelonés Vall d'Hebron, Rosa Boyé.
Los médicos también han acusado al consejero de Salud, Boi Ruiz, de intentar "maquillar" los efectos del recorte en las listas de espera. Ruiz anunció ayer la aplicación de un nuevo modelo de gestión de la lista de espera que suprime el tiempo de garantía de seis meses para las intervenciones más comunes y que fijará ese tiempo de garantía en función de la gravedad del paciente.
En solo seis meses, el mismo periodo que lleva CiU en el Gobierno y durante el que empezó a aplicar recortes en sanidad, la lista de espera ha aumentado el 23% pasando de unos 56.000 pacientes a casi 70.000. La única vía para conservar la sanidad pública, han señalado los médicos, consiste en tratarla como al sector bancario, que ha sido financiado en momentos de dificultades de liquidez. "Nos obligan a convocar una huelga", ha protestado Boyé. "Así no podemos funcionar".
Todos los hospitales de referencia mantienen cerradas camas, quirófanos y servicios. El hospital de Bellvitge ha cerrado 100 camas, mantiene clausurados 6 quirófanos de 35 y ha dejado de operar a entre 2.000 y 3.000 personas por efecto de los recortes, pacientes que han pasado a engrosar la lista de espera. En Vall d'Hebron han cerrado 120 camas, desde abril se opera un 50% menos y se prevé que este año se dejen de realizar 5.000 operaciones quirúrgicas. El hospital Trias i Pujol mantiene cerradas 112 camas y ha reducido la actividad quirúrgica el 2,5% este año. En el Virgen de la Cinta Tortosa, por su parte, el 32% de las 250 camas están cerradas y las intervenciones se han reducido el 68%. "Es un retrato de lo que está ocurriendo en todos los hospitales públicos", destacó la representante sindical.
**Publicado en"EL PAIS"
Los médicos también han acusado al consejero de Salud, Boi Ruiz, de intentar "maquillar" los efectos del recorte en las listas de espera. Ruiz anunció ayer la aplicación de un nuevo modelo de gestión de la lista de espera que suprime el tiempo de garantía de seis meses para las intervenciones más comunes y que fijará ese tiempo de garantía en función de la gravedad del paciente.
En solo seis meses, el mismo periodo que lleva CiU en el Gobierno y durante el que empezó a aplicar recortes en sanidad, la lista de espera ha aumentado el 23% pasando de unos 56.000 pacientes a casi 70.000. La única vía para conservar la sanidad pública, han señalado los médicos, consiste en tratarla como al sector bancario, que ha sido financiado en momentos de dificultades de liquidez. "Nos obligan a convocar una huelga", ha protestado Boyé. "Así no podemos funcionar".
Todos los hospitales de referencia mantienen cerradas camas, quirófanos y servicios. El hospital de Bellvitge ha cerrado 100 camas, mantiene clausurados 6 quirófanos de 35 y ha dejado de operar a entre 2.000 y 3.000 personas por efecto de los recortes, pacientes que han pasado a engrosar la lista de espera. En Vall d'Hebron han cerrado 120 camas, desde abril se opera un 50% menos y se prevé que este año se dejen de realizar 5.000 operaciones quirúrgicas. El hospital Trias i Pujol mantiene cerradas 112 camas y ha reducido la actividad quirúrgica el 2,5% este año. En el Virgen de la Cinta Tortosa, por su parte, el 32% de las 250 camas están cerradas y las intervenciones se han reducido el 68%. "Es un retrato de lo que está ocurriendo en todos los hospitales públicos", destacó la representante sindical.
**Publicado en"EL PAIS"
Subscribe to:
Comments (Atom)
CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies
Copyright © Noticia de Salud